Aun Consulting
2459
Welby
4438
Value Creation
9238
Perseus Proteomics
4882
DMS
9782
(FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|
Operating Cash Flow (Indirect Method) | ||
Cash flow from continuing operating activities | ||
Net income from continuing operations | -31.54%125.71M | --183.62M |
Remuneration paid in stock | -175.29%-256K | --340K |
Other non cashItems | 89.46%-2.08M | ---19.72M |
Change In working capital | 57.05%-8.51M | ---19.82M |
-Change in receivables | 32.48%-6.31M | ---9.34M |
-Change in inventory | 5.07%-5.09M | ---5.37M |
-Change in other current assets | 155.36%4.07M | ---7.34M |
Interest paid (cash flow from operating activities) | -34.50%-1.08M | ---800K |
Interest received (cash flow from operating activities) | 67.61%295K | --176K |
Tax refund paid | -123.68%-81.31M | ---36.35M |
Cash from discontinued investing activities | ||
Operating cash flow | -59.65%48.57M | --120.37M |
Investing cash flow | ||
Cash flow from continuing investing activities | ||
Net PPE purchase and sale | -7,360.32%-205.31M | ---2.75M |
Net investment purchase and sale | -72.49%-18.6M | ---10.78M |
Net other investing changes | -132.10%-7.83M | --24.39M |
Cash from discontinued investing activities | ||
Investing cash flow | -2,234.80%-231.73M | --10.86M |
Financing cash flow | ||
Cash flow from continuing financing activities | ||
Net issuance payments of debt | 571.27%169.61M | --25.27M |
Net other financing activities | 10,050.00%199K | ---2K |
Cash from discontinued financing activities | ||
Financing cash flow | 590.86%169.01M | --24.46M |
Net cash flow | ||
Beginning cash position | 44.46%512.21M | --354.57M |
Current changes in cash | -109.09%-14.16M | --155.69M |
Effect of exchange rate changes | 35.11%2.64M | --1.95M |
Cash adjustments other than cash changes | ---- | --1K |
End cash Position | -2.25%500.69M | --512.21M |
Free cash from | -233.26%-156.74M | --117.62M |
Currency Unit | JPY | JPY |